PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10090785-1 1999 Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGFR protein tyrosine kinase together with published X-ray crystal data of quercetin (2) in complex with the Hck tyrosine kinase and of deschloroflavopiridol (3b) in complex with CDK2, a putative binding mode of the isoflavone genistein (1) was proposed. Genistein 326-335 epidermal growth factor receptor Homo sapiens 99-103 10226546-5 1999 Both genistein, a general tyrosine kinase inhibitor, and tyrphostin AG 1478, a tyrosine kinase inhibitor specific for EGFR, inhibited phosphorylation of EGFR in NCI-H596. Genistein 5-14 epidermal growth factor receptor Homo sapiens 153-157 9833772-0 1998 Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Genistein 52-61 epidermal growth factor receptor Homo sapiens 78-110 9833772-5 1998 In this regard, we sought to determine the effect of genistein, a naturally occurring dietary protein tyrosine kinase (PTK) inhibitor, on the growth and motility of human bladder cancer cell lines with diverse EGFR and p21ras expression phenotypes and corresponding invasive behaviors. Genistein 53-62 epidermal growth factor receptor Homo sapiens 210-214 9833772-8 1998 In addition, the growth and motility inhibitory effects of genistein and tyrphostin are observed preferentially in cells that overexpress the EGFR. Genistein 59-68 epidermal growth factor receptor Homo sapiens 142-146 9848510-3 1998 In membrane preparations from mammalian cells, genistein is a potent and specific inhibitor of tyrosine autophosphorylation of the epidermal growth factor (EGF) receptor. Genistein 47-56 epidermal growth factor receptor Homo sapiens 131-169 9607569-2 1998 We have shown previously that targeting the naturally occurring PTK inhibitor genistein to the EGFR-associated PTK complexes using the EGF-Genistein (Gen) conjugate triggers rapid apoptotic cell death in human breast cancer cells and abrogates their in vitro clonogenic growth. Genistein 78-87 epidermal growth factor receptor Homo sapiens 95-99 9607569-2 1998 We have shown previously that targeting the naturally occurring PTK inhibitor genistein to the EGFR-associated PTK complexes using the EGF-Genistein (Gen) conjugate triggers rapid apoptotic cell death in human breast cancer cells and abrogates their in vitro clonogenic growth. Genistein 139-148 epidermal growth factor receptor Homo sapiens 95-99 9588219-2 1998 In the present study, we evaluated the effect of EGF and genistein, a tyrosine kinase inhibitor, on cell proliferation, EGFR phosphorylation and its downstream signal MAP kinase activation and investigated the involvement of these processes in programmed cell death in a human pulmonary adenosquamous carcinoma cell line, NCI-H596. Genistein 57-66 epidermal growth factor receptor Homo sapiens 120-124 9588219-4 1998 Genistein abolished the ability of EGF to induce EGFR phosphorylation, to activate MAP kinase and to increase cell proliferation. Genistein 0-9 epidermal growth factor receptor Homo sapiens 49-53 9060993-7 1997 In contrast, tyrphostin AG1478 had no effect on SP-A levels despite a greater inhibitory effect than genistein on EGF receptor tyrosine autophosphorylation. Genistein 101-110 epidermal growth factor receptor Homo sapiens 114-126 9309250-0 1997 Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways. Genistein 0-9 epidermal growth factor receptor Homo sapiens 32-64 8702388-0 1996 Genistein, a tyrosine kinase inhibitor, reduces EGF-induced EGF receptor internalization and degradation in human hepatoma HepG2 cells. Genistein 0-9 epidermal growth factor receptor Homo sapiens 60-72 8702388-1 1996 In this work, using the ECL Western blotting assay system, it was found that genistein, a specific tyrosine kinase inhibitor, was able to inhibit EGF-induced EGF receptor degradation and tyrosine phosphorylation in human hepatoma HepG2 cells. Genistein 77-86 epidermal growth factor receptor Homo sapiens 158-170 7884565-2 1995 Genistein is a potent in vitro inhibitor of protein tyrosine kinase (PTK) activity, especially that of the epidermal growth factor receptor (EGF-R), having little effect on serine/threonine kinases. Genistein 0-9 epidermal growth factor receptor Homo sapiens 107-139 7884565-2 1995 Genistein is a potent in vitro inhibitor of protein tyrosine kinase (PTK) activity, especially that of the epidermal growth factor receptor (EGF-R), having little effect on serine/threonine kinases. Genistein 0-9 epidermal growth factor receptor Homo sapiens 141-146 7884565-3 1995 This led to the suggestion that genistein might exert its anti-cancer effects through inhibiting the activity of EGF-R PTK, or other crucial PTK"s in vivo. Genistein 32-41 epidermal growth factor receptor Homo sapiens 113-118 7884565-4 1995 Subsequent studies on intact tumor cell lines demonstrated that EGF-R and other growth factor receptors are able to transmit mitogenic signals in the presence of genistein. Genistein 162-171 epidermal growth factor receptor Homo sapiens 64-69 8297123-4 1993 Inhibition of the EGFR-associated tyrosine kinase by genistein and the tyrphostins RG-13022, RG-14620 and RG-50864 resulted in a dose-dependent growth inhibition with half maximal inhibition at 10 microM, 7 microM and 23 microM, respectively. Genistein 53-62 epidermal growth factor receptor Homo sapiens 18-22 3106339-3 1987 By contrast, genistein scarcely inhibited the enzyme activities of serine- and threonine-specific protein kinases such as cAMP-dependent protein kinase, phosphorylase kinase, and the Ca2+/phospholipid-dependent enzyme protein kinase C. When the effect of genistein on the phosphorylation of the EGF receptor was examined in cultured A431 cells, EGF-stimulated serine, threonine, and tyrosine phosphorylation was decreased. Genistein 13-22 epidermal growth factor receptor Homo sapiens 295-307 33486190-6 2021 Evaluation of the phosphorylation status of 49 different receptor tyrosine kinases showed that genistein selectively inhibited phosphorylation of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR). Genistein 95-104 epidermal growth factor receptor Homo sapiens 146-178 33486190-6 2021 Evaluation of the phosphorylation status of 49 different receptor tyrosine kinases showed that genistein selectively inhibited phosphorylation of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR). Genistein 95-104 epidermal growth factor receptor Homo sapiens 180-184 32276266-7 2020 Additionally, genistein dramatically decreased epidermal growth factor receptor (EGFR) expression and attenuated its down-stream signaling molecules STAT3, MDM2, Akt and JAK1/2 phosphorylation, resulting in inhibited nuclear translocation of STAT3 and MDM2, thereby inhibiting the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways. Genistein 14-23 epidermal growth factor receptor Homo sapiens 47-79 32276266-7 2020 Additionally, genistein dramatically decreased epidermal growth factor receptor (EGFR) expression and attenuated its down-stream signaling molecules STAT3, MDM2, Akt and JAK1/2 phosphorylation, resulting in inhibited nuclear translocation of STAT3 and MDM2, thereby inhibiting the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways. Genistein 14-23 epidermal growth factor receptor Homo sapiens 81-85 32276266-10 2020 Taken together, genistein suppressed the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways by decreasing EGFR expression, leading to cell apoptosis, cell cycle arrest, and proliferation inhibition in EsC cells. Genistein 16-25 epidermal growth factor receptor Homo sapiens 104-108 31611933-7 2019 Genistein in combination with gefitinib significantly inhibited cell viability, promoted apoptosis and reduced EGFR, vascular endothelial growth factor receptor and platelet-derived growth factor receptor phosphorylation. Genistein 0-9 epidermal growth factor receptor Homo sapiens 111-115 29693152-0 2018 Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors. Genistein 0-9 epidermal growth factor receptor Homo sapiens 44-48 27861885-3 2017 Previously the mitotic disturbance phenomenon induced by treatment with genistein was not fully explained by its inhibitory effect on EGFR. Genistein 72-81 epidermal growth factor receptor Homo sapiens 134-138 27861885-9 2017 These data suggest that genistein may be a promising anticancer drug candidate due to its inhibitory activity against Plk1 as well as EGFR and effectiveness toward cancer cells, especially those with p53-mutation. Genistein 24-33 epidermal growth factor receptor Homo sapiens 134-138 28255863-4 2017 Mechanistically, ammonia triggered EGFR/extracellular signal-regulated kinase (ERK) association and subsequent ERK phosphorylation were alleviated by genistein pretreatment. Genistein 150-159 epidermal growth factor receptor Homo sapiens 35-39 28240227-3 2017 Phosphorylation of the EGF receptor (EGFR) was inhibited even more effective in the presence of indomethacin and nimesulide than in the presence of genistein. Genistein 148-157 epidermal growth factor receptor Homo sapiens 23-35 28240227-3 2017 Phosphorylation of the EGF receptor (EGFR) was inhibited even more effective in the presence of indomethacin and nimesulide than in the presence of genistein. Genistein 148-157 epidermal growth factor receptor Homo sapiens 37-41 25401399-0 2014 Synthetic genistein glycosides inhibiting EGFR phosphorylation enhance the effect of radiation in HCT 116 colon cancer cells. Genistein 10-19 epidermal growth factor receptor Homo sapiens 42-46 25401399-1 2014 The need to find new EGFR inhibitors for use in combination with radiotherapy in the treatment of solid tumors has drawn our attention to compounds derived from genistein, a natural isoflavonoid. Genistein 161-170 epidermal growth factor receptor Homo sapiens 21-25 25401399-4 2014 Genistein derivatives inhibited clonogenic growth of HCT 116 cancer cells additively or synergistically when used in combination with ionizing radiation, and decreased EGFR activation. Genistein 0-9 epidermal growth factor receptor Homo sapiens 168-172 25401399-5 2014 Our preclinical evaluation of genistein-derived EGFR inhibitors suggests that these compounds are much more potent sensitizers of cells to radiation than the parent isoflavonoid, genistein and indicate that these compounds may be useful in the treatment of colon cancer with radiation therapy. Genistein 30-39 epidermal growth factor receptor Homo sapiens 48-52 24699889-3 2014 Genistein has been shown previously to inhibit GAG synthesis in MPS fibroblasts, presumably through inhibition of tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Genistein 0-9 epidermal growth factor receptor Homo sapiens 146-178 24699889-3 2014 Genistein has been shown previously to inhibit GAG synthesis in MPS fibroblasts, presumably through inhibition of tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Genistein 0-9 epidermal growth factor receptor Homo sapiens 180-184 24631489-7 2014 In docking analyses exploring the putative interaction with the tyrosine kinase EGFR, these novel modulators of barrier tightness showed very similar values compared to the known tyrosine kinase inhibitor genistein. Genistein 205-214 epidermal growth factor receptor Homo sapiens 80-84 22293631-1 2012 The soy compound genistein has been observed preclinically to inhibit bladder cancer growth with one potential mechanism being the inhibition of epidermal growth factor receptor phosphorylation (p-EGFR). Genistein 17-26 epidermal growth factor receptor Homo sapiens 197-201 22293631-10 2012 Genistein displayed a possible bimodal effect (more effective at the lower dose) on bladder cancer tissue EGFR phosphorylation that should be evaluated further, possibly in combination with other agents. Genistein 0-9 epidermal growth factor receptor Homo sapiens 106-110 21603581-0 2011 Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. Genistein 0-9 epidermal growth factor receptor Homo sapiens 20-52 21603581-8 2011 Our immunoblotting data suggest that increased proliferation and metastasis are linked to enhanced activities of tyrosine kinases, EGFR and its downstream Src, in genistein-treated groups. Genistein 163-172 epidermal growth factor receptor Homo sapiens 131-135 20138837-0 2010 Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Genistein 27-36 epidermal growth factor receptor Homo sapiens 121-125 19347870-1 2009 In previous studies on HeLa cells we demonstrated estrogen-responsiveness of the epidermal growth factor receptor (EGFR) gene, as 17beta-estradiol (E(2)) and selective estrogen receptor modulators (SERMs) genistein (G), daidzein (D), and 4-hydroxytamoxifen (4OH-T) modulated its transcription in a ligand- and estrogen receptor (ER) isoform-specific way. Genistein 205-214 epidermal growth factor receptor Homo sapiens 81-113 19347870-1 2009 In previous studies on HeLa cells we demonstrated estrogen-responsiveness of the epidermal growth factor receptor (EGFR) gene, as 17beta-estradiol (E(2)) and selective estrogen receptor modulators (SERMs) genistein (G), daidzein (D), and 4-hydroxytamoxifen (4OH-T) modulated its transcription in a ligand- and estrogen receptor (ER) isoform-specific way. Genistein 205-214 epidermal growth factor receptor Homo sapiens 115-119 19288574-0 2009 Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Genistein 0-9 epidermal growth factor receptor Homo sapiens 33-65 19288574-4 2009 The authors hypothesized that genistein, through the inhibition of NF-kappaB, could enhance the activity of EGFR-TKIs in NSCLCs. Genistein 30-39 epidermal growth factor receptor Homo sapiens 108-112 19288574-12 2009 CONCLUSIONS: The authors concluded that genistein enhances the antitumor effects of EGFR-TKIs in 3 separate NSCLC cell lines. Genistein 40-49 epidermal growth factor receptor Homo sapiens 84-88 18424208-3 2008 Therefore, the present in vitro-study was undertaken to determine, whether genistein and daidzein affect the mRNA expression of growth factor receptors (IGF-I receptor and EGF receptor) and their related growth factors in porcine skeletal muscle cell cultures. Genistein 75-84 epidermal growth factor receptor Homo sapiens 172-184 19149197-1 2008 Genistein is a high specific and noncompetitive inhibitor of epidermal growth factor receptor tyramine kinase domain (EGFR-TK). Genistein 0-9 epidermal growth factor receptor Homo sapiens 61-93 17934341-7 2007 Genistein, a protein tyrosine kinase (PTK) inhibitor, and PD153035, an EGFR inhibitor, also blocked the increase of TNF-alpha expression by TCDD, indicating the role of EGFR in TCDD-induced TNF-alpha expression. Genistein 0-9 epidermal growth factor receptor Homo sapiens 169-173 17295235-8 2007 Further determination of the molecular markers showed that TAM and genistein combination synergistically induced BT-474 cell apoptosis in part by synergistic downregulation of the expression of survivin, one of the apoptotic effectors, and downregulation of EGFR, HER2, and ERalpha expression. Genistein 67-76 epidermal growth factor receptor Homo sapiens 258-262 17234721-8 2007 In addition, genistein and TAM combination synergistically delayed the growth of breast tumor via decreased estrogen level and activity, and down-regulation of EGFR expression. Genistein 13-22 epidermal growth factor receptor Homo sapiens 160-164 16470170-11 2006 Finally, inhibition of EGFR activation by genistein reduces epidermal hyperplasia caused by topical retinoid treatment. Genistein 42-51 epidermal growth factor receptor Homo sapiens 23-27 16197614-5 2005 In addition to its estrogenic and/or antiestrogenic activities, genistein has been reported to inhibit steroidogenesis and block several protein tyrosine kinases, including epidermal growth factor receptor and src tyrosine kinases. Genistein 64-73 epidermal growth factor receptor Homo sapiens 173-205 15634453-0 2004 [The effects of genistein on epidermal growth factor receptor mediated signal transduction pathway in human ovarian carcinoma cells lines SKOV3 and its xenograft in nude mice]. Genistein 16-25 epidermal growth factor receptor Homo sapiens 29-61 15634453-3 2004 This study aimed to investigate the effects of genistein on the EGFR mediated signal transduction pathway and to clarify its mechanisms of proliferation inhibition on human ovarian carcinoma cell line SKOV(3) and its xenograft in nude mice. Genistein 47-56 epidermal growth factor receptor Homo sapiens 64-68 15634453-10 2004 It is suggested that interfering the expressions of some key signal molecules in EGFR mediated signal transduction system by genistein may account for its molecular foundation of proliferation inhibition in ovarian carcinoma. Genistein 125-134 epidermal growth factor receptor Homo sapiens 81-85 12709393-4 2003 The epidermal growth factor (EGF) receptor blocker genistein (10 microM) abolished the effect of CNP (0.2 +/- 0.4 mV, n = 7), and comparable results were obtained with 10 microM daidzein (n = 8). Genistein 51-60 epidermal growth factor receptor Homo sapiens 4-42 11348889-6 2001 Ang II-induced PAI-1 mRNA upregulation was inhibited by BAPTA-AM, genistein, and AG1478, suggesting that intracellular calcium, tyrosine kinase, and epidermal growth factor receptor transactivation are involved. Genistein 66-75 epidermal growth factor receptor Homo sapiens 149-181 11170137-6 2001 RESULTS: Treatment of cells with silymarin, genistein or EGCG at 100-200 microM resulted in a complete inhibition of TGFalpha-caused activation of erbB1 followed by a moderate to strong inhibition (10-90%) of Shc activation without an alteration in their protein levels. Genistein 44-53 epidermal growth factor receptor Homo sapiens 147-152 11170137-7 2001 Silymarin and genistein, but not EGCG, also inhibited (10% to complete) ERK1/2 activation suggesting that these agents impair erbB1-Shc-ERK1/2 signaling in DU145 cells. Genistein 14-23 epidermal growth factor receptor Homo sapiens 126-131 10982794-9 2000 In contrast, genistein, a general tyrosine kinase inhibitor, significantly attenuated the tyrosine phosphorylation of EGFR in response to HPO. Genistein 13-22 epidermal growth factor receptor Homo sapiens 118-122 11007941-10 2000 In androgen-independent human prostate carcinoma DU145 cells, silymarin, genistein, and EGCG resulted in a significant to complete inhibition of transforming growth factor-alpha-caused activation of membrane receptor erbB1 followed by inhibition of downstream cytoplasmic signaling target Shc activation and a decrease in its binding with erbB1, without an alteration in their protein expression. Genistein 73-82 epidermal growth factor receptor Homo sapiens 217-222 11007941-10 2000 In androgen-independent human prostate carcinoma DU145 cells, silymarin, genistein, and EGCG resulted in a significant to complete inhibition of transforming growth factor-alpha-caused activation of membrane receptor erbB1 followed by inhibition of downstream cytoplasmic signaling target Shc activation and a decrease in its binding with erbB1, without an alteration in their protein expression. Genistein 73-82 epidermal growth factor receptor Homo sapiens 339-344 11007941-11 2000 Silymarin and genistein also inhibited ERK1/2 activation, suggesting that these agents impair the activation of erbB1-Shc-ERK1/2 signaling in DU145 cells. Genistein 14-23 epidermal growth factor receptor Homo sapiens 112-117 10381396-8 1999 Both genistein as a wide spectrum protein tyrosine kinase inhibitor and AG1478 as a specific EGFR tyrosine phosphorylation blocker inhibited activation of EGFR and MAP kinase by HNE. Genistein 5-14 epidermal growth factor receptor Homo sapiens 155-159